Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcenestrant phase 1/2 study in ER-positive HER2-negative advanced breast cancer
2024-512997-89-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of amcenestrant in breast cancer (10 arms), sponsored by Sanofi. Primary endpoints: Dose Limiting Toxicities (DLTs), Objective Response Rate (ORR) and 1 more. Started Oct 2024; status: completed.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-512997-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512997-89-00.